{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:40:11Z","timestamp":1791945611339,"version":"4.3.4"},"reference-count":70,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>\n            BRCA1-associated protein 1 (BAP1) and Enhancer of zeste homolog 2 (EZH2) proteins are associated with the Polycomb repressive complex (PRC), and both have key roles in cell cycle and DNA repair pathways, so variants in\n            <jats:italic toggle=\"yes\">BAP1<\/jats:italic>\n            and\/or\n            <jats:italic toggle=\"yes\">EZH2<\/jats:italic>\n            could lead to tumorigenesis. Somatic and germline variants in these genes have been associated with uveal and cutaneous melanoma, mesothelioma, renal cell carcinoma (\n            <jats:italic toggle=\"yes\">BAP1<\/jats:italic>\n            loss-of-function variants), and lymphoma, leukemia, and triple-negative breast cancer (\n            <jats:italic toggle=\"yes\">EZH2<\/jats:italic>\n            gain-of-function variants). Loss of\n            <jats:italic toggle=\"yes\">BAP1<\/jats:italic>\n            function in the murine model has been shown to lead to an overexpression of\n            <jats:italic toggle=\"yes\">EZH2<\/jats:italic>\n            mRNA. Tazemetostat is a selective EZH2 inhibitor currently approved for the treatment of follicular lymphoma in the third line. The effects of tazemetostat have been studied in clinical trials for patients with\n            <jats:italic toggle=\"yes\">BAP1<\/jats:italic>\n            and\n            <jats:italic toggle=\"yes\">EZH2<\/jats:italic>\n            pathogenic variants with malignant mesothelioma and it has shown significant results when used in combination with poly (ADP-ribose) polymerase inhibitors on breast cancer cell lines. The interaction of BAP1 and EZH2 and the efficacy of tazemetostat show great potential for the future of cancer treatment for patients harboring variants in those genes due to the more aggressive nature of those tumors and the lack of targeted treatments.\n          <\/jats:p>","DOI":"10.1200\/po-24-00845","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T19:59:11Z","timestamp":1750190351000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["BRCA1-Associated Protein 1 and Enhancer of Zeste Homolog 2: Pathway Interaction and Therapeutic Intervention in Breast Cancer, Mesothelioma, and Lymphoma"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6560-6800","authenticated-orcid":true,"given":"Elizabeth Casey","family":"West","sequence":"first","affiliation":[{"name":"Healthcare Genetics and Genomics, School of Nursing, Clemson University, Clemson, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Evangelista","sequence":"additional","affiliation":[{"name":"Thoracic Surgery, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7794-6641","authenticated-orcid":true,"given":"Annalisa","family":"Campanella","sequence":"additional","affiliation":[{"name":"Thoracic Surgery, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9383-5554","authenticated-orcid":true,"given":"Filippo","family":"Lococo","sequence":"additional","affiliation":[{"name":"Thoracic Surgery, Catholic University of the Sacred Heart, Rome, Italy"},{"name":"Thoracic Surgery, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5226-1817","authenticated-orcid":true,"given":"Laura","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8119-0472","authenticated-orcid":true,"given":"Diana","family":"Ivankovic","sequence":"additional","affiliation":[{"name":"Healthcare Genetics and Genomics, School of Nursing, Clemson University, Clemson, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Farrell","sequence":"additional","affiliation":[{"name":"Healthcare Genetics and Genomics, School of Nursing, Clemson University, Clemson, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Parker","sequence":"additional","affiliation":[{"name":"School of Nursing\/Center for Research on Health Disparities, Clemson University, Clemson, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Boccuto","sequence":"additional","affiliation":[{"name":"Healthcare Genetics and Genomics, School of Nursing, Clemson University, Clemson, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_4_2_2","unstructured":"KEGG Pathway: Pathways in cancer\u2014Homo sapiens (human). https:\/\/www.genome.jp\/kegg-bin\/show_pathway?hsa05200"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2405231121"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcae045"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.09.012"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102091"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140257"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy171"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0466-6"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02025-6"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102402"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.120047"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0814-6"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00885-9"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-021-00954-7"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-21005-w"},{"key":"e_1_3_4_17_2","unstructured":"Tatton-Brown K Hanks S Ruark E et al: Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height. https:\/\/core.ac.uk\/display\/1496161"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2011.11.018"},{"key":"e_1_3_4_19_2","first-page":"6662","article-title":"Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma","volume":"7","author":"Fan TY","year":"2014","unstructured":"Fan TY, Wang H, Xiang P, et al: Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma. Int J Clin Exp Pathol 7:6662-6670, 2014","journal-title":"Int J Clin Exp Pathol"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2015.11.002"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.01.006"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216706"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3459"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.609834"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2016-203866"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-02966-w"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-020-00709-4"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9471"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0221"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-022-01354-0"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0620-3"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2021.07.011"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3947"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2021.600073"},{"key":"e_1_3_4_35_2","volume-title":"GeneReviews\u00ae [Internet]","author":"Pilarski R","year":"2016","unstructured":"Pilarski R, Carlo MI, Byrne L, et al. BAP1 tumor predisposition syndrome. In: Adam MP, Feldman J, Mirzaa GM, et al, eds. GeneReviews\u00ae [Internet]. Seattle, WA: University of Washington; (2016). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK390611\/"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1933744100"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2011.12.004"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00567"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.116054"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10070-z"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.912"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-23-611"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.03.014"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13304-022-01369-4"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00119-X"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.12.014"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10173801"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2012.12.037"},{"key":"e_1_3_4_49_2","unstructured":"National Cancer Institute (NCI): Prospective evaluation of high resolution dual energy computed tomographic imaging noninvasive (liquid) biopsies and minimally invasive surgical surveillance for early detection of mesotheliomas in patients with BAP1 tumor predisposition syndrome. clinicaltrials.gov. 2023. https:\/\/clinicaltrials.gov\/study\/NCT04431024"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1220"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071252"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-073120"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1870-5"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2022.09.002"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30145-1"},{"key":"e_1_3_4_56_2","volume-title":"A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate\/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function\u2014Full Text View","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate\/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function\u2014Full Text View. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04241835"},{"key":"e_1_3_4_57_2","volume-title":"Cancer Treatment Uses, Side Effects, Dosage","author":"Tazemetostat","unstructured":"Tazemetostat: Cancer Treatment Uses, Side Effects, Dosage. https:\/\/www.medicinenet.com\/tazemetostat\/article.htm"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-2990-1"},{"key":"e_1_3_4_59_2","volume-title":"A Phase 1\/2 Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas. clinicaltrials.gov","author":"Constellation Pharmaceuticals","year":"2022","unstructured":"Constellation Pharmaceuticals: A Phase 1\/2 Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas. clinicaltrials.gov. 2022. https:\/\/clinicaltrials.gov\/study\/NCT04104776"},{"key":"e_1_3_4_60_2","volume-title":"A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2 in Patients With B-Cell Lymphomas. clinicaltrials.gov","author":"Constellation Pharmaceuticals","year":"2022","unstructured":"Constellation Pharmaceuticals: A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2 in Patients With B-Cell Lymphomas. clinicaltrials.gov. 2022. https:\/\/clinicaltrials.gov\/study\/NCT02395601"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.5061"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157853"},{"key":"e_1_3_4_63_2","volume-title":"A Single Arm, Open Label, Single-Center Dose-Exploratory Clinical Study of Linperlisib in Combination With EZH2 Inhibitor SHR2554 in the Treatment of Relapsed\/Refractory Peripheral T-Cell Lymphoma. clinicaltrials.gov","author":"Institute of Hematology & Blood Diseases Hospital, China","year":"2024","unstructured":"Institute of Hematology & Blood Diseases Hospital, China: A Single Arm, Open Label, Single-Center Dose-Exploratory Clinical Study of Linperlisib in Combination With EZH2 Inhibitor SHR2554 in the Treatment of Relapsed\/Refractory Peripheral T-Cell Lymphoma. clinicaltrials.gov. 2024. https:\/\/clinicaltrials.gov\/study\/NCT06712173"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00134-X"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15040"},{"key":"e_1_3_4_66_2","volume-title":"A Phase 1 Study of Tazemetostat in Patients With Relapsed or Refractory B-Cell Non-Hodgkin\u2019s Lymphoma. clinicaltrials.gov","author":"Eisai Co, Ltd","year":"2022","unstructured":"Eisai Co, Ltd: A Phase 1 Study of Tazemetostat in Patients With Relapsed or Refractory B-Cell Non-Hodgkin\u2019s Lymphoma. clinicaltrials.gov. 2022. https:\/\/clinicaltrials.gov\/study\/NCT03009344"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-185057"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166991"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.12.014"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00277-7"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3945817"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-24-00845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T19:59:24Z","timestamp":1750190364000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-24-00845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":70,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1200\/PO-24-00845"],"URL":"https:\/\/doi.org\/10.1200\/po-24-00845","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2024-11-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400845"}}